# Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

> **NCT01302964** · PHASE3 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 30 (actual)

## Conditions studied

- Autism Spectrum Disorders

## Interventions

- **DRUG:** Placebo
- **DRUG:** Mirtazapine

## Key facts

- **NCT ID:** NCT01302964
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2017-10-10
- **Final completion:** 2017-10-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302964, "Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01302964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*